BTIG Initiates Coverage On Sunesis Pharmaceuticals


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target.

Analyst Hartaj Singh believed the “current valuation reflects the Street assuming a 15-20 percent probability of vosaroxin approval in the US and EU. We believe the probability of US/EU approval for lead-asset vosaroxin is 50 percent based on the robustness of the VALOR trial and the high unmet need in relapsed/refractory (R/R) acute myeloid leukemia (AML).”

Singh noted that the “VALOR trial did miss its primary endpoint, a cause for concern regarding FDA and European Medicines Agency (EMA) approval. However, we believe the totality of the VALOR data will sway regulators favorably to approve vosaroxin in patients >60 years old (~2/3 of R/R AML patients).”

“We believe the company will be breakeven by 2017 – assuming US/EU approval – and will see rapid operating leverage due to the small cost base of operating in R/R AML, an orphan disease-like area. We see adjusted EPS of $6.74/share in 2019, 3 full years post-launch,” according to the analyst note.
 
The key risk to Singh’s thesis “would be FDA and/or EMA non-approval of vosaroxin in R/R AML.”

The $5.50 price target was based on a “stand-alone vosaroxin valuation” at $10/share and applied a “50 percent probability of approval plus cash.”

Sunesis Pharmaceuticals, Inc. traded at $2.80 in the after market session, up 5.26 percent.
 

 


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Price TargetInitiationAnalyst RatingsbtigHartaj Singh